Obalon Therapeutics, Inc.
OBLN · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 404.2% | -51.6% | -63.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 63.2% | 36.8% | 10.1% | 40.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -83.3% | -723.6% | -694.4% | -404.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -89.1% | -776.7% | -721.6% | -410.7% |
| EPS Diluted | -13.83 | -1.59 | -5.03 | -19.64 |
| % Growth | -769.8% | 68.4% | 74.4% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |